ReviewPathology oncology research : POR2024
Stereotactic body radiotherapy in lung cancer: a contemporary review.
Review in Pathology oncology research : POR, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.
- Pooled it
- The future is not always uniform: rethinking radiotherapy through spatial fractionation.Nature reviews. Clinical oncology · 2026Review
- Metastasectomy versus stereotactic body radiotherapy for lung metastases: a systematic review and meta-analysis of reconstructed time-to-event data on overall and progression-free survival.Journal of thoracic disease · 2026Article
- Assessing the technical capability of a room- and a gantry-mounted kV imaging device for intra-fractional fluoroscopy during stereotactic lung radiotherapy at a C-arm linear accelerator.Physics and imaging in radiation oncology · 2026Article
- [Research Advances in ctDNA-MRD Monitoring in Local Treatment for Non-small Cell Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2026Review
- Long-term pulmonary function decline after stereotactic body radiation therapy for lung tumors.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2026Article
- Integrating Surgery and Ablative Therapies for the Management of Multiple Primary Lung Cancer: A Systematic Review.Cancers · 2025Review
- Application of respiratory motion management technology for patients with lung cancer treated with stereotactic body radiotherapy (Review).Oncology letters · 2025Review
- Medicaid Expansion is Associated with Differences in Local Therapy for Non-small Cell Lung Cancer.Annals of surgical oncology · 2025Article
- The Impact of Radiation Therapy on Intrathecal Drug Delivery System Functioning and Safety.Current pain and headache reports · 2025Review
- Stereotactic ablative radiotherapy versus conventional fractionated radiotherapy for clinical early-stage non-small-cell lung cancer: a population-based study.Thoracic cancer · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The treatment of early stage non-small cell lung cancer (NSCLC) has improved enormously in the last two decades. Although surgery is not the only choice, lobectomy is still the gold standard treatment type for operable patients. For inoperable patients stereotactic body radiotherapy (SBRT) should be offered, reaching very high local control and overall survival rates. With SBRT we can precisely irradiate small, well-defined lesions with high doses. To select the appropriate fractionation schedule it is important to determine the size, localization and extent of the lung tumor. The introduction of novel and further developed planning (contouring guidelines, diagnostic image application, planning systems) and delivery techniques (motion management, image guided radiotherapy) led to lower rates of side effects and more conformal target volume coverage. The purpose of this study is to summarize the current developments, randomised studies, guidelines about lung SBRT, with emphasis on the possibility of increasing local control and overall rates in "fit," operable patients as well, so SBRT would be eligible in place of surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.